ABL Bio Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, ABL Bio stock has a consensus rating of "Buy" and an average price target of ₩223,200. The average 1-year stock price forecast is 145.01% higher than the current stock price, while the lowest is ₩86,000 (-5.60%) and the highest is ₩280,000 (+207.35%).

Price Target: ₩223,200 (+145.01%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₩86,000	₩223,200	₩260,000	₩280,000
Change	-5.60%	+145.01%	+185.40%	+207.35%

Analyst Ratings

The average analyst rating for ABL Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	May '25	Jul '25	Nov '25	Jan '26	Feb '26	Apr '26
Strong Buy	1	1	1	2	2	2
Buy	4	4	5	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	6	5	5	5

Financial Forecast

Revenue This Year

94.12B

from 79.35B

18.61%

from 79.35B

Revenue Next Year

114.54B

from 94.12B

21.70%

from 94.12B

EPS This Year

-121.80

from -734.00

EPS Next Year

214.25

from -121.80

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	5.33B	67.30B	65.55B	33.40B	79.35B	94.12B
Revenue Growth	-	1,162.19%	-2.61%	-49.04%	137.55%	18.61%
Operating Income	-51.19B	908.00M	-2.62B	-59.38B	-40.39B	-12.00B
Net Income	-43.56B	3.21B	-2.65B	-55.53B	-37.81B	1.00B
EPS	-	-	-	-	-734.00	-121.80
Free Cash Flow	-	63.17B	-37.71B	-62.86B	-52.54B	35.00B
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.

Revenue Forecast

Revenue	2026	2027	2028
High	138.0B
Avg	94.1B
Low	27.0B

Revenue Growth

Revenue Growth	2026	2027	2028
High	73.9%
Avg	18.6%
Low	-66.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-121.80
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-